Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer

International Journal of Molecular Medicine

Volumn 39, Issue 4, 2017, Pages 861-868

  Bai, Shuang ^a   Qiang, Feng ^b   Pan, Xin Yan ^b   Zou, Hong ^b   Chen, Hao Bin ^b   Peng, Wang ^a   Zhou, Xin Liang ^a   Hong, Yan Ling ^c   Song, Shu Ling ^b   Yang, Ju Lun ^a,b,c  

^a Kunming University of Science and Technology   (Japan)

^b KUNMING GENERAL HOSPITAL   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Mutation; Overexpression; P21Ras; Wild type

Indexed keywords

K RAS PROTEIN; PROTEIN P21; HRAS PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL POLYP; COLORECTAL TUMOR; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INTESTINE MUCOSA; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85018469229     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2017.2903     Document Type: Article

References (52)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
4. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, et al: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238-3245, 2007.
5. Del Vecchio Blanco G, Paoluzi OA, Sileri P, Rossi P, Sica G and Pallone F: Familial colorectal cancer screening: When and what to do? World J Gastroenterol 21: 7944-7953, 2015.
6. Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, et al: Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 110: 648-655, 2014.
7. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
8. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
9. Ohnishi T, Tomita N, Monden T, Ohue M, Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, et al: A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Cancer 75: 341-347, 1997.
10. Puerta-García E, Cañadas-Garre M and Calleja-Hernández MA: Molecular biomarkers in colorectal carcinoma. Pharmacogenomics 16: 1189-1222, 2015.
11. Liu X, Jakubowski M and Hunt JL: KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 135: 245-252, 2011.
12. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
13. Chang YS, Chang SJ, Yeh KT, Lin TH and Chang JG: RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. Onkologie 36: 719-724, 2013.
14. Palmirotta R, Savonarola A, Ludovici G, De Marchis ML, Covello R, Ettorre GM, Ialongo C and Guadagni F: Concurrent mutation in exons 1 and 2 of the K-ras oncogene in colorectal cancer. Folia Histochem Cytobiol 49: 729-733, 2011.
15. Salhab N, Jones DJ, Bos JL, Kinsella A and Schofield PF: Detection of ras gene alterations and ras proteins in colorectal cancer. Dis Colon Rectum 32: 659-664, 1989.
16. Thomas RJ, Liu YS, St Clair F, Norris PM, Valentine R and Phillips WA: Frequency and clinico-pathological associations of ras mutations in colorectal cancer in the Victorian population. Aust NZ J Surg 67: 233-238, 1997.
17. Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, et al: RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121: 1195-1203, 2015.
18. Kiaris H and Spandidos D: Mutations of ras genes in human tumors (Review). Int J Oncol 7: 413-421, 1995.
19. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM and Ogino S: NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19: 157-163, 2010.
20. Glarakis IS, Savva S and Spandidos DA: Activation of the ras genes in malignant and premalignant colorectal tumors. Oncol Rep 5: 1451-1454, 1998.
21. Boidot R, Chevrier S, Julie V, Ladoire S and Ghiringhelli F: HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report. Int J Colorectal Dis 31: 1245-1246, 2016.
22. Spandidos DA, Sourvinos G, Tsatsanis C and Zafiropoulos A: Normal ras genes: Their onco-suppressor and pro-apoptotic functions (Review). Int J Oncol 21: 237-241, 2002.
23. Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S, Cao D, Zhou L, Zhang A, Liu D, et al: Overexpression of wild-type EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget 7: 3884-3896, 2016.
24. Lim SO, Park YM, Kim HS, Quan X, Yoo JE, Park YN, Choi GH and Jung G: Notch1 differentially regulates oncogenesis by wild-type p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology 53: 1352-1362, 2011.
25. McDermott U, Longley DB and Johnston PG: Molecular and biochemical markers in colorectal cancer. Ann Oncol 13 (Suppl 4): 235-245, 2002.
26. Yang JL, Liu DX, Zhen SJ, Zhou YG, Zhang DJ, Yang LY, Chen HB and Feng Q: A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues. BMC Cancer 16: 131, 2016.
27. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL and McCarty KS Jr: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46: 5419-5425, 1986.
28. Ferretti G, Felici A, Papaldo P, Fabi A and Cognetti F: HER2/neu role in breast cancer: From a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19: 56-62, 2007.
29. Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, et al: Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 25: 592-598, 2014.
30. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461-471, 2013.
31. Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, et al: Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31: 1947-1953, 2013.
32. Zhang F, Yu Y, Xing L and Chen M: Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure. Int J Clin Exp Med 8: 16140-16148, 2015.
33. Socinski MA: Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 13: s4597-4601, 2007.
34. Boland W and Bebb G: The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 4: 289-298, 2010.
35. Hand PH, Thor A, Wunderlich D, Muraro R, Caruso A and Schlom J: Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci USA 81: 5227-5231, 1984.
36. Viola MV, Fromowitz F, Oravez S, Deb S and Schlom J: ras oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med 161: 1213-1218, 1985.
37. Ohuchi N, Thor A, Page DL, Hand PH, Halter SA and Schlom J: Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 46: 2511-2519, 1986.
38. Ghosh AK, Moore M and Harris M: Immunohistochemical detection of ras oncogene p21 product in benign and malignant mammary tissue in man. J Clin Pathol 39: 428-434, 1986.
39. Ohuchi N, Hand PH, Merlo G, Fujita J, Mariani-Costantini R, Thor A, Nose M, Callahan R and Schlom J: Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. Cancer Res 47: 1413-1420, 1987.
40. Johnson TL, Lloyd RV and Thor A: Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues. Am J Pathol 127: 60-65, 1987.
41. Scambia G, Catozzi L, Benedetti Panici P, Ferrandina G, Almadori G, Paludetti G, Cadoni G, Distefano M, Piffanelli A and Mancuso S: Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: Correlation with histopathological features and epidermal growth factor receptors. Br J Cancer 69: 995-999, 1994.
42. Yang JL, Pan XY, Zhao WX, Hu QC, Ding F, Feng Q, Li GY and Luo Y: The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo. Int J Oncol 48: 1218-1228, 2016.
43. Sammoud S, Khiari M, Semeh A, Amine L, Ines C, Amira A, Lilia K, Taher K, Sabeh M and Saadia B: Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. Appl Immunohistochem Mol Morphol 20: 146-152, 2012.
44. Allen DC, Foster H, Orchin JC and Biggart JD: Immunohistochemical staining of colorectal tissues with monoclonal antibodies to ras oncogene p21 product and carbohydrate determinant antigen 19-9. J Clin Pathol 40: 157-162, 1987.
45. Sun XF, Wingren S, Carstensen JM, Stål O, Hatschek T, Boeryd B, Nordenskjöld B and Zhang H: ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma. Eur J Cancer 27: 1646-1649, 1991.
46. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, et al: Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 25: 2008-2014, 2014.
47. Elsabah MT and Adel I: Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Natl Canc Inst 25: 51-56, 2013.
48. Hirvikoski P, Auvinen A, Servomaa K, Kiuru A, Rytömaa T, Makkonen K and Kosma VM: K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma. Anticancer Res 19: 685-691, 1999.
49. Okulczyk B, Kovalchuk O, Piotrowski Z, Myśliwiec P and Chyczewski L: Clinical usefulness of K-RAS mutation detection in colorectal cancer and in surgical margins of the colon. Rocz Akad Med Bialymst 49 (Suppl 1): 52-54, 2004.
50. Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, et al: Wild-type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL-8 secretion via JAK2 activation. Cell Rep 12: 511-524, 2015.
51. Spandidos A and Wilkie NM: The normal human H-ras1 gene can act as an onco-suppressor. Br J Cancer Suppl 9: 67-71, 1988.
52. Spandidos DA, Frame M and Wilkie NM: Expression of the normal H-ras1 gene can suppress the transformed and tumorigenic phenotypes induced by mutant ras genes. Anticancer Res 10: 1543-1554, 1990.